Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 29Myelodysplastic Syndromes 10Advanced Solid Tumors 8Leukemia, Myelomonocytic, Chronic 6Myeloproliferative Disorders 5Advanced Solid Tumor 5Ovarian Neoplasms 4Neoplasms 4Multiple Myeloma 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumour 4Small Cell Lung Carcinoma 3Recurrence 3Leukemia, Monocytic, Acute 3Triple Negative Breast Neoplasms 2Thrombocythemia, Essential 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Neoplasm Metastasis 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Acute 2Leukemia, Biphenotypic, Acute 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Breast Neoplasms 2

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Locally Recurrent Breast Cancer × Injections × 90 days × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡